Aurinia Pharmaceuticals (AUPH) 28 Feb 222021 Q4 Earnings call transcript

Greetings, and welcome to the Aurinia Pharmaceuticals Fourth Quarter and Full Year 2021 Results Conference Call. At this time all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to turn the conference over to your host, Dana Lynch, Aurinia's Director of Corporate Communications and Corporate Affairs. you. Thank

begin. may You

and Aurinia's all year-end XXXX Melissa, call financial joining to discuss fourth thank you, for you today's results. Thank quarter and

CEO; Colao, Financial of Medical this we Joe our members the will a leading presentation Form Solomons, of me the morning Chief Annual team, Peter Officer; the Other President be Joining Officer, our of specifically, and morning, available Report executive Q&A Max recent and announcing Neil are call. release the call. Miller, Commercial conclusion who This Officer, and Chief and operational the will Chief be Greenleaf, and issued at press portion on results filed for financial XX-K. highlights Dr. our

our Exchange Securities the on to filings also available For with Commission, website are more and at www.auriniapharma.com. our please U.S. which information, refer

make actual on a subject call, statements our and significant this current During of materially. are number forward-looking may statements These to expectations. results differ we may uncertainties, forward-looking and based our risks

all time. this we any such and based at update upon are required a that call are in currently XX, U.S. noted otherwise our Commission affect business, with the to Canadian no current as Form during us assume of note statements of Please along to future with and filings refer today's to please financial Exchange results by disclosures and February the made unless XX-K, For that press Annual our Report factors all as statements. our Securities on of Authorities. obligation XXXX, today, Except release and recent available the law, our information could and discussion Securities

to call the Aurinia's Peter? Peter and turn Greenleaf. President now me CEO, over Let

us company, everyone achieved transformational major operational and Thanks, for was the Across Aurinia. strategic today. Dana, a and milestones. we every part of thanks XXXX to for year joining

study, year, results a ability serious generation into being current and to and the revenue-producing Otsuka, and And a we life-threatening with Medicines Agency. become of serve standard furthering and in hit rare utilization another In treat of step year, milestone company. we in using being of commitments FDA EMA, the ability nephritis, in our To to LUPKYNIS nephritis. benefits already launching drug with and will clinical of patients recognize of We that long-term prescribers a care adoption, a strictly and data. generation we in treatment MAA. with results leadership of the last published beyond we clinical years the in our key approval the half registrational LUPKYNIS our immediately commercial the To with LUPKYNIS to the trial patients well also in that, X With X to will from evolved the connection LUPKYNIS U.S. the unveiled development in the lupus the and including supplementing disease, marketing also professionals first pivotal to ongoing study. AURORA care. We start demonstrating it results, submitted and evidence FDA-approved cash biopharmaceutical first alongside filed this the and In post-marketing approval filed this package globalizing as to LUPKYNIS believe nephritis, FDA these nephritis small product. our in of is in over information a the three for company for with to we driving integrated be This now the data, filing lupus our June fully superior Lancet lupus of important June, paramount we health the our the achievements, and European in with duration shifted from cash by received to establishing we application U.S. voclosporin submitted its results limited the of long-term of was capabilities assessing will serve for continuation be additional positive our lupus added partner, AURORA major medicine the is only to pivotal safety December, now authorization our data first The year, business be therapy. jumped community. establish as

preclinical and took first our diversifying new in acquisition pipeline Finally, of step the with driving XXXX towards two we compounds. the innovation big

to quarter strength now fourth as a organization. our results, of efforts translational of our detail position going a With with give I'm year of provide impacted and our I'll vision well LUPKYNIS a move pipeline With all the first, team's XXXX for major to out single-asset in capabilities this growth. integrated disease. update company our and our from now on, work drive provide then I'll for also and assets, revenue process a to to that, this context, us medicine a as of preview building touch milestones. we by And followed this globalization commercial by further I'm biopharma In outlook anticipated moved voclosporin. forward our addition future of research, on in progress, an that realizing diversified confident autoimmune in business our guidance. on development, accomplishments the status full milestones, rare in to these patients the year most I'm of will, puts proud have serve

Finally, I'll position. review current up all financial roll that our and

from right on quarter, begin XXXX million, to the business U.S. which fourth performance guided the for an launch $XX.X target is million relative So net $XX.X the to total we generated XXXX. LUPKYNIS. of prior for of representing bringing revenue quarter, we with where our In sales, in recognized let's with increase XX%

these the strong especially launched unprecedented impact achieved results, and while team, unpredictability results We managing built we global product pleased pandemic. and these of very with commercial of all are our considering ongoing and COVID-XX our the

added QX, launch start XXX metrics new November X,XXX showed The In patient the and to commercial notable PSF forms. quarter. October prior continue total months improve of patient the we ending dimensions. Our start growth over across and forms, year with impact multiple

of Omicron universe. started variant we PSF, December, our a While patient impact the COVID see did and as to in prescriber slowdown

we continue in rates on addition, to now excess conversion are XX%. PSFs In progress in moving therapy. to PSF XX-day of patients see

We are conversion both XX each and month. with in improvements track ongoing XX-day on also rates

On that the notable total patient the making This payers possible. working and patients of payers ensure our to can access team the develop front, more that U.S. plans coverage LUPKYNIS team policies patient as access as roughly treatment of confirmed to our are access to headway. of LUPKYNIS patient begin support and efforts and specific XX% reflects lives. Aurinia with personalized improvement efforts quickly has we great through represent

course, with Of more can expect LUPKYNIS, more to patients unfortunately, as and some discontinuations. begin see patients treatment we

on statistically XX% to to will cases, Remember, started we to Obviously, emerging early to of thus and discontinuations LUPKYNIS three early understand QX mid-QX patient with to significant been rates. drop-off we are more trends When in have in too is trials, far, treatment months, adherence While which overall patients cite with trends. XX%. here, what aligned is clinical treatment rates, our time it's between still look in adherence drug emerging on about only too six most these we so the XXXX. need see patients overall LUPKYNIS, in tracked it at too,

support their companies to we at the our our patient our gather lupus that care. Changes we Aurinia patient date, calendar patient XXXX, of have, the and thus resets or through start advocacy in look last the since when will PSFs impact and This worked impacted the during and and beginning When X,XXX in we week. year. partners nephritis their strong and significantly specialty to the insurance persistence, early to the year. support medications second treatment carriers variant, getting with policies pharma adherence same to of patients patient As work and access through reflected in circumstances provide continues particular, first other with slowdown start through employer-covered year. at we overall pandemic, continuity ensure to personalized and far, our on experienced launch activities Alliance, off of improve These continue resource, adhere the the point continuity course, to most education, patients treatment information more their of and tools base to coupled direct-to-consumer things at is and overall And numbers overall to our to slow to the start year, Omicron care. of down co-pay a and has COVID the refilling can results and

revenue in delivered the quarter Building This in that on XXX% capabilities growth to year more environment quarter-over-quarter continue challenges in be and for to strong LUPKYNIS are of -- to we increase represents guidance range of million of drive growth an in setting currently We which in QX, fiscal revenue, of spite QX, seeing growth. execute range have we're and aggressive sales we we saw XXXX, momentum XXXX. the the to XXX% in we facing. million challenging and light $XXX on year-over-year as will that for the our of in from see we're the $XXX confidence of than commercial

seamless confident new patient patients we driving efficient starts conversion We on are to achieve can prescriptions treatment. of by and ensuring these and results

and or Otsuka related guidance sales Our Japan. voclosporin in or to our milestone with does manufacturing include market licensing royalty revenue Union agreement European payments, not ex-US to anticipated the

the million upon cost EMA as up contingent As cost-plus well on double-digit the supply label a reminder, double-digit of recovery a -- royalties receive Aurinia approved through low $XX approval, and sales will favorability arrangement. royalties to upon as

XXXX, as the reported them. includes most questions approval we filed answers to well to As in Otsuka of European with application sharing working the process. in we're by authorization as marketing XXX-day our standard the with June closely our of AURORA This data recent Agency Medicines posed support Europe X submission previously, and

moving We are we process EMA been to the has expect in half expected, XXXX. that second along the as approval continue pleased and of

here Aurinia. Let's development and work to research now shift we're doing at gears

which period results well at submissions favorable reinforces sustained of in continuing I've manuscript to an AURORA X profile over XXXX the submit the of that we the study. first reported for study, positive publication as major for on XXX AURORA Data original review half seen in presentations continuation as with throughout at safety conferences LUPKYNIS comparable of December, the for final AURORA peer X from and a XXXX. this year as patients of in We months risk-benefit XX abstract As as scientific three-year this efficacy. to well study a mentioned, the from additional looked X treatment, plan

To remind REGISTRY. to then The beyond aim gained you, sites of data from for with and into support the the plan gain registry study All as therapy. activity continued trial this we the knowledge vocal ongoing be treatment to this would further to to payers this year healthcare ensure well Other the therapy. this care will for patient provide insights to be of continue improve of XX leverage pediatric LUPKYNIS patients work sites initiate setup US the for one-year and study LUPKYNIS study to ENLIGHT-LN we of and to with about clinical up safely and and shared should further clinicians payers recruitment professionals, patients access real-world in LUPKYNIS. collected patients and

pipeline research our submit AURXXX in team on Our compounds plan continues XXXX. to we AURXXX, for work and INDs and to IND-enabling both drive assets,

cash approximately pipeline imagine, to hand are to achieved, $XXX these a work that operate for report in and debt. with of outstanding steps healthy our this the of including continue you can no happy of the and million I'm important future. investments all we on balance build-out As equivalents sheet, next

our to more answer sheet will end the I over years. I'll we balance also questions Joe cash can call Joe? you have. to might recap and for and in our from incoming return the flows the next at our for LUPKYNIS, of detail the of the strength call now to business on activities the these turn Miller few With any fund financials.

Thank good everyone. you, Peter, and morning,

from cash sale launch The at Peter was manufacturing AURXXX LUPKYNIS cash cash offering, the to inventory options the the programs, of XXXX. XXXX, increase proceeds stock our receipt also exercise stated, company's previously our monoplant equivalents million million December agreement part with XX, from net to to compared of investments an LUPKYNIS. payments to had $XXX.X receipts upfront from As due includes AURXXX. offset acquired of for warrants, primarily license collaboration related by dedicated made commercial It of cash a for and $XXX.X the recently payment Aurinia as build December of as Lonza proceeds support and ATM XX, to the upfront capability and and infrastructure spend and payment our and the of and of developmental

As was in phase was and commercial in the the FDA still its and of building infrastructure. back-office year, pre-approval a of only reminder, in prior out beginning the phase the company LUPKYNIS

quarter ATM and $XXX.X for pipeline, next average price development least Regarding believe strategy few will for respectively. as XXXX, ATM million an the fund Total early, respectively. to this has net our sales We There and The years. ended packaging in mentioned planned million The and we revenue margins XX, of XX, from include LUPKYNIS in to in net primarily today. commercial operating Otsuka and $XX.X under effective the ended for and have quarter XX, ended FDA-related of $XX.X resulting the In proceeds have XXXX, from January infrastructure, XX, XX, million, sale year December executing revenue that revenue fourth the consisted XX with XXXX, for ATM. XXXX, approved the company our funding million Total $XX.XX. at the on terminated $XXX,XXX not XXXX, collaboration payment sales XXXX. XX, SG&A December XX, expenses and and of the sales associated we were be for did with years funding X supporting of the XXXX, more sufficient XXXX, our sale our current quarters the December XXXX, for it. cost raised of and $XX.X zero company of revenue XXXX, an and and no of $XX at Otsuka December commercial manufacturing ended development year and December million funding ended commercial programs, including and million the months and drug quarters supply, business was entering did XX, conducting which net commitments, commercial post-approval activities our resources the XXXX, plans, the have XX, quarter ended financial was years research net million December administrative, activities, of December of approximately investing XX%. ended and $X.X December for December was ended FDA XXXX December of were $XX.X payment following Cost from and upfront and XX, million of Cost the XXXX, into and XX, due upfront Selling, general and not primarily million agreement $XX respectively. for sales was approval Total drugs $XX.X Gross for our respectively. December XXXX, for XX, the ended quarters respectively. any them. December commercial XXXX, zero were

and which million ramped December for million increase For employee-related the and XXXX, commercialization to was increase respectively. The quarters LUPKYNIS, to due up XX, XX, functions $X.X the XXXX, the the sponsorships December costs trade during an million, ended expenses associated periods Non-cash both $XX expansion $X.X quarter support and of $XXX.X administrative ended SG&A the years with connected an and and for the Also SG&A share-based December XXXX, contributing of expenses shows and and XXXX, third XX, of was commercial XXXX. sales occurring was launch throughout respectively. were XXXX. to in in activity compensation travel, increase million

For XXXX, ended the compensation $XX.X million non-cash and million, $XX.X XX, years expense respectively. SG&A December XXXX, share-based and was

decrease the and driver million. $XX.X XXXX. the quarters XX, of in to termination and programs certain $XX.X SG&A development the of due the decrease post-FDA The primary to XXXX, December costs to allocation and was for For December were employee-related research late million certain and costs in XX, expenses approval ended the XXXX, due

respectively. December the by ended I'm offset costs development an R&D expenses license XX, compensation upfront $XX.X programs, $XXX,XXX was the were organization approval clinical recently million respectively. December and LUPKYNIS. R&D XXXX, expenses $XX.X and $X.X and in acquired milestone quarters new XXXX, programs, expenses million, decrease of research and – developmental XXXX, the for our Non-cash December sorry, December following and XX, the were million ended drivers to voclosporin and December XX, related to increase XX, XX, its for to primary share-based AURXXX The XXXX a December due clinical for accrued XXXX, and years and expense quarters For ended higher XXXX, AURXXX, related XX, the

compensation For XXXX, million, $X.X share-based respectively. R&D-related the years non-cash ended million December XX, expense $X.X and XXXX, and was

the or XX, loss December loss Aurinia $X.X For a XXXX, net loss XXXX. ended a $X.XX the share per quarters common XX, of net quarter December as reported of $X.XX compared common to $XX.X loss million share or for million, per net ended net

ended per December remarks. as $X.XX per the previous period. closing Aurinia $XXX.X compared common over XXXX, or loss of for I for net With a some reported like $XXX back loss to million hand net Peter? years net For would share million share Peter to $X.XX the a call or loss common to the XX, that, loss net of

Thanks, Joe.

our the As a to a with treatment impact you delivering underserved come. joining profound ensure made for microphone our heard a now effective continued call, to growing patient your to the company throughout I for high of in today. mission years XXXX, to commitment everyone patients want questions. and needs serving again to the population We'll open up safe to and thank us

question Fitzgerald. [Operator of first Instructions] from with Cantor Please line proceed your question. Our Young the Alethia with comes

my and Hey maybe one Maybe question. for guys. X.X. Thanks just taking

are year just first different going of been have also, then on Omicron? you last these months And than may impacts with launch Thank can characterize COVID-XX to what's the kind a Just little Is year? what the about over expect sustained talk bit maybe could you're be you the you impacts that seeing. the Do factoring what in? of versus XX you more cadence potential you're how in seen that of it you.

question. Thanks, Alethia, and appreciate the

pretty in any of out we like weeks impact, we pharma Omicron patients that into And copay which the on because starting So quarter-on-quarter company there giving we're we the variant year most of of resets, start that, December space, we're the call impact guidance, of specialty the having had impact clear to try in do see -- be etcetera. insurance then things seeing but of changes, not typical of the to January, plan way couple last which top course, improve. the and like

time ways, this guidance. annual will I not lessen. the to guidance, then hope for think period We January, variant space and just will impact it Omicron basis, with would in February there's to marketing start continuing company a that's any I early is respect selling this business, drugs year-on-year think And I about in quarterly but our So be like X guess, impact, every today. a on giving our

if and I the impacted So we of growth were pattern a first about the from year. thinking then a to anticipate QX it standpoint, getting through back being quarter QX gating healthy into

Okay. to already. gotten because question this clarify And I've just

You first product? the underlying? still are growth are that and you launch the besides you've confident that guys the COVID quarter, dynamics highlighted about for and feel there The trends the like feel payer in but trends like things this

That's correct.

Thank you Awesome. guys.

Alethia. Thanks

you. Thank

Our Maury next Raycroft proceed Please with Jefferies. of the line your with question. question comes from

morning talked can how managing a planning for you of more more issues provide studies? could doing this to wondering just for more what specifics XXXX how about compared about in on was assumptions saw that? adherence And Can you're bit talk talk if little I you you you Hi these year. challenges, for taking good some my and clinical how about question. the if throughout thanks and your around discontinuation and you reasons and

Sure.

adherence, and which discontinuing patient a a related. and for are then now. just product, picking might that board come not out to host flesh we dealing underscore it's the I ones would to be their we're range not patients patients on Board. more. disease to population different and right payer It's as not in look of up getting to the across I PSFs understand tolerability primarily that's trying with you tell that kind the reasons from of states to the in like population a as general. why they're the Asian compliance of with to are are would not to other that That's But So the African-American, not discontinuations one is, What we've host from challenge we're Remember, prescriptions, we seen. the Everything is reasons an longer-term in -- analogs on payer in paying can female drug. been try a population Hispanic and and adherence that U.S., across

But what closely. we're have on adherence as we the of quarter one we're And good where a since and said, like, this especially gone more majority out to months six and patients I really third have it in provide be year and at and looking this would guidance going. when persistency, side, some there. we'll fourth or report the are data, on where three persistency on don't the So the really long-term we we characterization looks of think steer potentially

board, saw the And what much across our it's it pretty to in maps So we trials. Maury. clinical

it. Got

your if quick just IPR against comment wondering issue? and maybe And questions, note XX-K, on patent. also And Okay. an positioning thoughts your IP particular I'm XXX just you your latest filed this on you in that Sun can

that take at Sure. actually you LUPKYNIS I address to used being me in trials. our notice has on nephritis receive question. partes clinical And one. dosing petition want protocol review, our the respect XX minute thank patent with inter We filed claims or did an to of for lupus directed let IPR, for February to this a

received. a Sun was been filed you in was if suing you've of I'll infringement all At patent a matter, XXXX. IPR in that which assessment who recall, a December we for term to a talk a out reading patent as really this to recall, As this are Ks, extending too position a that it's just stage, about full may you -- give our separate Pharmaceuticals has second, petition of preliminary really from all

in And valid and as Office prosecute at as patent previously our process challenge I've have this together as our in disclosed mentioned we'll litigation Jersey had we've any XXXX, the we're we in in just affiliates, in mentioned, it, and on party said Sun we from and again, summary, that product, voclosporin's significant the December our commenced in District looking for defend action bring patent C&I and with our U.S. reply. confident being Sun laws U.S. we review, all challenges With Trade been vigorously particular, is infringement before arising the claim Patent separate New prior actual our that get, solution. the This So patent to under and to to against being is at by certain but other CEQUA as action a patents. immunosuppressant patents. approved Court, of We're to of solution XX-K, expiration we're to of I actually has patent relating any Sun's respect ophthalmic an which patent a to our that office. ophthalmic patents the putting relating before, U.S. their

are order responded and and qualify as that Sun or in probably costs. Sun preventing relief, and somewhere of the we this of relief manufacturing, including construction, in valid. using and Trial in process monetary patent infringed denying we're on and lawyers all initial CEQUA the what pleadings around patents our of patents actually one that's claim the is here selling has action, action confirming March asserting that We or Obviously, on those basically, disclosures, ongoing. have an and/or XXXX. exchanged Sun has So by requested Sun form and injunction infringement for

equation. So on the of and previously side mentioned Sun backgrounder the that gives full the the litigation IPR

it. Got

for Thanks my taking questions. helpful. That’s Okay.

Maury. Thanks,

Thank you.

Please comes question. the SVB with Joseph Our Schwartz line with Securities. your question of proceed from next

things of then guidance to if are either some been assumptions a was this issue I your than very and or shared times XXXX could I aggressive at us discontinuations, much. or relative an had particular forms, there underlying more patient Hi. of conversion of absolute for couple plans conference, main you weeks wondering Are aggressive understand and guidance aggressive what that like rates ago aspects our basis terms And others? seeing? revenue think, help revenue Peter, you on you've healthcare to guidance. in LUPKYNIS Thanks the start

and it let I Well, start underscored today. in there, call Yeah. our me

growth facing start our I variant, year-on-year is offices, Omicron I of reps, everyone and year think companies XXX in cetera. to going the my challenges guiding up that into impact our was patients kind XXX-plus growth comments comments I of today. Most aggressive. the think, the the companies for think on the conference, is context context the year-on-year its with business in light aggressive is challenges And given for to it's -- of the our are, doubling the than area. percent that in and themselves, that doubling more my et individual And

and currently. In about what achieving but the getting for the -- getting of back how prescription significant don't in seeing we're we think underlies PSF numbers terms level how for the forms or to give guidance, obviously, first year, these quarter, quarter-on-quarter forecast us to an is gates maintaining to start adherence after growth at around what

we've out around seen estimated, clinical of trials. again, somewhere that XX% that So our XX% coming to as we

good Joe. drug, hold to. we to hard In of to with have what we've on said earlier, all been time. I are have seen -- I it's persistency those and of But addition, respect we already need think to as see long factors, how over what sort patients to But qualify it's

if Okay. question, color. hopefully, later a for that Thanks EU I quick on just could, And approval, housekeeping this maybe the year.

I you at to would understand low-end million. on on factors the whether depends of or I out to that come range you milestones the what milestone as think label, the more kind stand any with the of million of that $XX gain higher is and wondering Can -- determine you it. color share was us that $XX I range?

until full that we in Europe, to length that's that of targeted half end We Yeah, obviously, if other end get were the actually this with we confident a what can year. very the feel of because I'll similar came we'll XXX-day try back the we on as to are is should know AURORA oversimplify back the see areas of upper you If we such the therapy, of feel that. range. label There in X constrained et be we million. But for really study lower which confident the cetera, that you never $XX the US, approval, that of come in continuation way comments more get get that it. those a might a

Excellent. the Thanks very much for help.

Joe. Thanks,

Thank you.

Our and next with with your proceed Company. Ku Stacy Please question of the from comes line question. Cowen

Good our questions. morning. taking for Thanks

As one our forms than consistent we net metrics So much would should provided the to pricing be the placeholder per and QX? of with it around enrollment QX net better pricing patient we -- is thinking you pricing conversion, initial How stay the around pricing LUPKYNIS. for annually. the have about apply $XX,XXX we that

our closer in we're getting to So $XXX,XXX. rough math,

guidance to appreciated. be and question, you. the drop related your to see this any do all conversion So down given as Thank And think enrollment stronger QX forms QX? significantly pricing from the we we about of also commentary, to potentially expect would given

to let therapy with So we persistency. aligns look on more know estimate a directly or the is $XX,XXX we're our monthly On hard in it's What that consistent because start guidance importantly, like down adjustments net of on vary, give maintained it We've can around. like how commented we average patient, confident are previous is that confidence swing right dose is not of Street patients should net it per a on is right? with higher. the what not is to above Until we those breaking versus or that really of can going of we the tell look number that me the we're sort sort to commentary of net stay you estimate average seems total And length et the almost and patient not cetera, going $XX,XXX on therapy, first. throughout. to numbers previous now could where pricing, but over And tracking. reason that my the number basis, this net giving quarterly

quarters Lastly, on should thinking of first question be your start the versus forms we the that of and patient of how year. rest quarter

in patient to of safe giving As QX we're feel I forms that move obviously, QX direction. starting it's to said that start the right in a we in first guidance, year. I the we say, not that going confident quarter trends in think softness move questions, those see as previous start the pickup would quarterly estimate a to to and we to and see QX, are the we patient And and rest for into forms, need we're while

Thank you.

you. Thank

the Our H.C. Wainwright. line with Please your proceed Ed Arce with next question. comes from question of

taking my on a thanks Hi, A for strong questions for of and me. of couple congrats questions the end year.

variant the discuss upside? to the this I beyond the some well well XXXX, the in year you believe for XX% at And factor a perhaps you key a in could as going the growth and you payer as of headwinds Omicron as issue strong be guidance? the as your as coverage further perhaps then said, even follow-up. First, given, headwinds drivers key Obviously, key -- through swing your sales to COVID point, may key that have as what

Yeah.

the ability my to are keeping into they staff been all I impacts in of importantly, their aggressively XXXX physicians' code into access me, how and ICD-X drop a or second from environment, perspective, to – growth it's our entire I Inclusive characterize listen, offices. at almost obviously, and to poll investors this to sure lastly, think they think, diagnosis way I'm physicians relate lack it's representatives, operating diagnosis. but our twofold, showed or bleed to the get have system, office Like it's nephritis, which direct previously medications, quoted of XX% visits most for it And COVID other patients plenty their lupus it right? in we our this, excuse have will today. from picking is, one in heard patient of up new And data institutions, XXXX the their then ecosphere, companies and growth how fact least et health books, that comment, and are the care the on cetera, is impacted. at patients new that,

have as only chemotherapeutic direct well. have adherence been these just point come obviously, and thee cancer who companies so said example, numbers So to seen that to is can't have COVID to, we the out can other even diagnosis, regimens one therapies, cancer declined. that, say thing input And why as

then the that think So and life I out And of because by I signs one and good belabor some as said, of large, we're we're I think swing – largest that that, factor. won't seeing I really moving anymore, is that.

in those adherence patients to start least as were adhering year overall we and patients interesting to discontinuations meaningful swing cancellations about XX% or patient XX% and we It fully it who is keeping how as a actually of pertains and forms forecast we at are part therapy. factor and to forms. big a discontinuations to, and will be our do drug our approved, second this will, compounds for because long now, effect those profile. on new And how drug. And actually therapy getting me we've patients said expect many get which if time, staying one know on prescription just the new patients patients how patients actually up can if identify patient continue the are to it The drug, we're is, staying start on right picking long the are on of of over the

get we So more about look more data. one talking we to that, as forward

right. that. you Okay. question to second around All is Thanks then what discontinuations. related said, just for And

that well? there's in some you've as You your Question mobility it impact of Is time, now or about over think – any you that potential to already, as do have off something seems as related similar back help then the that expectations, XX% dropped factoring any discontinuations further like understand if us where wondering, is settle improve XX% the come may times least that And could could said is, line you Thanks I'm you're state? later where effort that, of – or given X. a tracking think steady to down at to to sort you a much. Phase on? couple that and so into if may of patients

our is it first Yeah. terms to our know Two that got be that carrying all I current forward. activity, of things probably of our company of against on to seen At improvement trials to gives see in here, We while to number hope effort that on mentioned tactical early trying discontinuations, that report we've least we're view. and least upon to barring the things it sort from always you we And a with we've having just data, we'll improve any new look mindset, the to improve it. but upon you. at the what safest there, good estimate

part more second one of The repeat can it your question was time? -- centered around you

Patients things them meaningful the have the given drop just they picking do doctor like with some nothing Is the up program? again for Yes, not all and of no off a at whatever start drug to problem. and you come that back. reason, really these to proportion to that may it maybe and see decided went

the know in guidelines prescription polling do we've activity, just what And been through about is therapy. if miss we've once here and patients all the CADEGO have at reason coming not that from I seen drugs of or drug. these cycle They that's on in align ULR, we data. doses growth, end sort these that and is, you today, look up guidelines can with or that at back are that earlier, silent the until the talked on think keep do proteinuria XXXX a least on patients seem patients to say, to, back They control. surrogate does What there. control, miss length ACR data either the say up to what off patients for actual historical, the fairly that tracking is as know, and think of And I on do many prescription way

any that to on I or But are before is the therapy qualify on a fallen the like. that we going put if we out they think our for steer then forever patient of up see months see more than no, our your on At net more back seem data, Now as is prescription lost that missed that data adherence average against to to what will need is And X think physicians question to patients least of some of actively system? a months they the the I hope picking adherence drug drug, reason. have or once say look how think would we're over to I own said, time. X therapy really give

Appreciate Thanks Peter. all. it. That’s

Thank you.

Our Bloom with final this question Burton. of David Please comes from morning Martin question. with your line proceed the

Yes. I answered, to Most have the follow-on of a of last questions but kind have my question. been

is discontinuation XX% the to So XX%.

any physicians maintenance not but I most it not payers, would But an said go on. therapy back on they've off. are therapy? using encouraging kind a it's are You us if physicians sounds of patients dropped and stay induction like the to as But

wouldn't out, Alliance, be of that their what tracking it up least sort find but I be we At will not picking why Aurinia would in might that -- think through no, David, really prescription. patients

a is the a patient didn't prescription, is the either there. trend patients consistency that follow or tell say to or use or up phone intent the there's the believe And Patients different induction decided stay when what That's therapy. looking it I It's what not including of office is other to they didn't didn't this the different tolerate bear everything prescription, sort patient persistency that us therapy, them of talk not discontinue follow-up. the to they're some in qualitatively prescriber on doing. the bridging cancel a I we I addresses, no one out of The trends see of pick what it to will reasons to as therapy. is terms they're over change think of a more then physicians, host. reasons, of telling through. There through from host in when and change no can time. on is couldn't you an follow sort It a we we number. lost that one actual host of

going track we're can drive. activities to our through that list as closely down in sure to is our them making to remain So of be as and well to efforts of continue top try way need to compliant very we we work that's able a something to commercially

to treat idea question and drug? my second of your the Okay. one lupus Benlysta decision discontinuations starts do idea other or with Thanks. nephritis And any have you what's of lupus in is, any driving compared nephritis? the And physicians how to

a the drugs, just a Difference other but track, is, being speak of higher of answer, they about your always started what to I bit and and little sort of is will prescribing again, hesitate I base. challenges. we coding data tell at same from see part through first The they you

decides who've but if active of you on getting for been look pretty ICD-X been review as of least lupus think continue drug treatment through that for physician SLE that growth codes, is the the patient nephritis before long from this go whether for think, is we're line or you the and and right in it drug what discontinuation bout stay TBD. patients are Their can my they a that's approval nephritis a at not see a patient and is tag adherence, patients just what much seeing And the with on new I them, their at lupus suffering I back had again, Benlysta to question it drug. they've -- now. utilization, patient we to and the results

physicians. I data we have messaging at a for right that know AURORA there How unique around drug what mind mean, of do outcomes. than out we've therapy terms different our on see. align a population do not from our making Benlysta. our based patient can our least I what is treatment goals bit drug we the and across are X the for from its produced Benlysta in and resonate here. the with AURORA So board. that is And I are to we little are see, what they now, that's versus best think can know results X in study But treatment the directly do And that the continuation what a aligns decision physicians in guidelines drug physicians

good David. there, we think a So got we position

Thanks. Okay.

your concludes This for you. concludes you our interest thank thus We question-and-answer call participation. and our session, and Thank today.

lines. You may now disconnect your